Translational immunology : mechanisms and pharmacologic approaches /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Tan, Seng-Lai (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Waltham, MA : Academic Press is an imprint of Elsevier, [2016]
Temas:
Immunology.
Immunopharmacology.
Immunity > drug effects
Immunotherapy > methods
Translational Research, Biomedical
Allergy and Immunology
Immunologie.
Immunopharmacologie.
HEALTH & FITNESS > Diseases > General.
MEDICAL > Clinical Medicine.
MEDICAL > Diseases.
MEDICAL > Evidence-Based Medicine.
MEDICAL > Internal Medicine.
Immunology
Immunopharmacology
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front Cover; Translational Immunology: Mechanisms and Pharmacologic Approaches; Copyright; Contents; Contributors; Preface; Section A: Human Immunology; Chapter 1: Systems Immunology; 1. Introduction; 2. Immune System is a Distributed and Decentralized Network that Protects Against Disease and Provides a Readout on Health; 2.1. Immune cells are distributed and specialized; 2.2. Immune system connects to all aspects of health and disease; 2.3. Commensal organisms; 2.4. Infectious diseases; 2.5. Allergic diseases; 2.6. Autoimmune diseases; 2.7. Inflammatory diseases; 2.8. Cancer
  • 2.9. Metabolic diseases2.10. Neurological diseases; 2.11. Connections between the immune system and other organ systems; 3. High-Throughput Technologies and Techniques for Systems Immunology; 3.1. Genomic profiling of immune system genes; 3.2. Transcriptional profiling of immune cells; 3.3. High-throughput technologies to profile immune cells; 4. Controlling the Immune System to treat Disease; 4.1. Vaccination to control infectious disease; 4.2. Immunotherapy to manipulate surveillance and control cancer; 4.3. Biologics to control autoimmune disease
  • 4.4. Drugs or other therapeutics to control asthma and allergy4.5. Drugs or other therapeutics to aid transplantation and resist rejection; 4.6. Drug repurposing; 4.7. Cellular therapies; 5. Immune monitoring; 5.1. Understanding global health challenges; 5.2. Predicting, tracking, and preventing emerging epidemics; 5.3. Identifying baseline states; 5.4. Monitoring for healthy aging and longevity; 5.5. Monitoring for critical care situations; 6. Conclusion; References; Chapter 2: Congenital Immunodeficiency Diseases: Crossroad of Infection, Autoimmunity, and Hyperinflammation; 1. Introduction
  • 2. Clinical Features of Autoimmune and Inflammatory Manifestations in PID3. Mechanisms Leading to Autoimmunity and Hyperinflammation in PID; 3.1. Increased apoptosis and decreased clearance; 3.1.1. Complement defects; 3.1.2. Chronic granulomatous disease (CGD); 3.2. Tendency for hyperinflammation; 3.2.1. Chronic granulomatous disease (CGD); 3.2.2. Omenn syndrome; 3.3. Impaired B or T cell tolerance checkpoints; 3.3.1. Defects in B cell tolerance that induce autoimmunity in PID; 3.3.2. Defects in T cell tolerance that induce autoimmunity in PID
  • 3.3.3. Defects in multiple tolerance checkpoints that induce autoimmunity in PID4. Current treatment strategies for autoimmunity in PID; 5. Investigational treatment strategies for autoimmunity in PID; 5.1. Small molecule inhibitors; 5.2. Gene therapy; 5.3. Cell-based therapy; 5.3.1. T regulatory Type 1 (Tr1) cells; 5.3.2. Virus-specific T cells; 6. Summary Statement; References; Chapter 3: Phenome-Wide Association Study; 1. Introduction; 2. Phenotyping from the Medical Record; 2.1. History of the classification of the human phenome; 2.2. Phenotyping from ICD data

Ejemplares similares